Bratteby L E, Foucard T, Lönnerholm G
Eur J Respir Dis. 1986 Apr;68(4):239-47.
The effect of adding ipratropium bromide to treatment with beta-2-adrenoceptor agonists was studied in 13 asthmatic children in a double-blind cross-over trial. In the acute phase of the study inhalation of salbutamol 0.1 mg/kg followed by inhalation of 0.25 mg of ipratropium bromide was found to improve pulmonary function variables to a significantly greater extent than salbutamol followed by placebo. The combined therapy also provided significantly better protection than salbutamol plus placebo against exercise-induced asthma. Maintenance treatment with ipratropium bromide (two inhalations four times daily, 20 micrograms per inhalation) in combination with oral terbutaline and aerosolized salbutamol did not alleviate asthmatic symptoms or pulmonary function variables to a degree beyond that achieved with the beta-stimulants alone. There were no side effects associated with the ipratropium bromide treatment. These data suggest that higher doses of ipratropium bromide than are presently used should be tested for maintenance treatment of chronic asthma.
在一项双盲交叉试验中，对13名哮喘儿童研究了在使用β2肾上腺素能受体激动剂治疗的基础上加用异丙托溴铵的效果。在研究的急性期，发现吸入0.1mg/kg沙丁胺醇后再吸入0.25mg异丙托溴铵，与吸入沙丁胺醇后再吸入安慰剂相比，肺功能指标改善程度明显更大。联合治疗对运动诱发哮喘的预防效果也明显优于沙丁胺醇加安慰剂。异丙托溴铵（每日4次，每次2吸，每吸20μg）联合口服特布他林和气雾剂沙丁胺醇进行维持治疗，在缓解哮喘症状或改善肺功能指标方面，并不比单独使用β激动剂效果更好。异丙托溴铵治疗未出现副作用。这些数据表明，对于慢性哮喘的维持治疗，应测试比目前使用剂量更高的异丙托溴铵。
